Fresenius SE & Co. KGaA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius SE & Co. KGaA
England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.
- In Vitro Diagnostics
- Medical Devices
- Other Names / Subsidiaries
- APP Pharmaceuticals, Inc.
- Asia Renal Care Ltd.
- Fresenius Kabi Pharmaceuticals Holding, Inc.
- Fresenius Medical Care
- Fresenius Medical Group AG
- Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
- Xenios AG